BRCA1 Protein

• 

  Subject Areas on Research

  • A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. 
  • A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. 
  • Ablation of the Brca1-Palb2 Interaction Phenocopies Fanconi Anemia in Mice. 
  • An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene. 
  • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. 
  • BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines. 
  • BRCA1 and BRCA2 mutations in ovarian cancer patients from China: ethnic-related mutations in BRCA1 associated with an increased risk of ovarian cancer. 
  • BRCA1 expression is not directly responsive to estrogen. 
  • BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. 
  • BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. 
  • BRCA1 mutations in primary breast and ovarian carcinomas. 
  • Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. 
  • Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence? 
  • Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations. 
  • CRISPR/Cas9-Mediated BRCA1 Knockdown Adipose Stem Cells Promote Breast Cancer Progression. 
  • Cell cycle control of BRCA2. 
  • Charting the landscape of tandem BRCT domain-mediated protein interactions. 
  • Comparing Coordinated Versus Sequential Salpingo-Oophorectomy for BRCA1 and BRCA2 Mutation Carriers With Breast Cancer. 
  • Comprehensive annotation of BRCA1 and BRCA2 missense variants by functionally validated sequence-based computational prediction models. 
  • Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer. 
  • Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. 
  • Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer. 
  • Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test. 
  • Development of human protein reference database as an initial platform for approaching systems biology in humans. 
  • Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer. 
  • Estimating the number of potential family members eligible for BRCA1 and BRCA2 mutation testing in a "Traceback" approach. 
  • Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. 
  • Genetic/familial high-risk assessment: breast and ovarian. 
  • Germline Genetic Testing: What the Breast Surgeon Needs to Know. 
  • Human ovarian cancer of the surface epithelium. 
  • Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. 
  • Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. 
  • Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. 
  • Identification of six new susceptibility loci for invasive epithelial ovarian cancer. 
  • Impact of Patents and Licensing Practices on Access to Genetic Testing for Inherited Susceptibility to Cancer: Comparing Breast and Ovarian Cancers to Colon Cancers 
  • Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. 
  • Improving indel detection specificity of the Ion Torrent PGM benchtop sequencer. 
  • Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance. 
  • Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. 
  • Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. 
  • Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. 
  • Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1. 
  • Low levels of BRCA1 protein expression predict a worse prognosis in stage I-II colon cancer. 
  • Managing hereditary ovarian cancer risk. 
  • MicroRNA miR-24-3p reduces DNA damage responses, apoptosis, and susceptibility to chronic obstructive pulmonary disease. 
  • Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. 
  • Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. 
  • Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. 
  • Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ. 
  • Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. 
  • Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. 
  • Pilot study of rapid MR pancreas screening for patients with BRCA mutation. 
  • Pioneering geneticist Mary-Claire King receives the 2014 Lasker~Koshland Special Achievement Award in Medical Science. 
  • Posttraumatic stress associated with cancer history and BRCA1/2 genetic testing. 
  • Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. 
  • Probing structure-function relationships in missense variants in the carboxy-terminal region of BRCA1. 
  • Real-world treatment patterns of maintenance therapy in platinum-sensitive recurrent ovarian cancer. 
  • Refining the role of BRCA1 in combating oxidative stress. 
  • Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha. 
  • Repair versus Checkpoint Functions of BRCA1 Are Differentially Regulated by Site of Chromatin Binding. 
  • Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. 
  • Risk factors for ovarian cancers with and without microsatellite instability. 
  • Screening for the breast cancer gene (BRCA1) using a biochip system and molecular beacon probes immobilized on solid surfaces. 
  • Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks. 
  • Surface-enhanced Raman scattering substrate based on a self-assembled monolayer for use in gene diagnostics. 
  • Survival Benefit of Germline BRCA Mutation is Associated with Residual Disease in Ovarian Cancer. 
  • Systematic Analysis of Splice-Site-Creating Mutations in Cancer. 
  • The genetic attributable risk of breast and ovarian cancer. 
  • Trends in screening breast magnetic resonance imaging use among US women, 2006 to 2016. 
  • Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome. 
  • Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. 
• 

  Keywords of People

  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Moorman, Patricia Gripka, Professor Emeritus in Family Medicine and Community Health, Duke Cancer Institute